3 completed, 1 not yet recruiting. 2 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Influenza Prophylaxis: new trials by email Literature Review of Influenza Prophylaxis trials Research Report on Influenza Prophylaxis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting Baloxavir Marboxil, Oseltamivir - Influenza, Influenza Prophylaxis | Not applicable | Not yet recruiting | Capital Medical University | 372 | 2025-01-05 | 2025-01-07 |
| INNA-051 Influenza Challenge Study INNA-051, Placebo - Influenza Prophylaxis | Phase 2 | Completed | ENA Respiratory Pty Ltd | 123 | 2022-02-28 | 2023-01-18 |
| Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection Vaccination with Fluval AB suspension for injection - Influenza Prophylaxis | Phase 4 | Completed | Fluart Innovative Vaccine Ltd, Hungary | 120 | 2013-08-22 | 2021-04-05 |
| Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe Stratis Jet Injector, Needle and Syringe, 2011-2012 Fluzone trivalent inactivated influenza vaccine - Influenza Prophylaxis | Phase 4 | Completed | PharmaJet, Inc. | 83 | 2012-01-01 | 2019-06-20 |
Cross Infection (1) · Influenza, Human (1)
Disease Attributes (1) · Iatrogenic Disease (1) · Infections (1) · Orthomyxoviridae Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
INNA-051 (1) · Injections (1) · Needles (1) · Oseltamivir (1) · Syringes (1) · Vaccination (1) · baloxavir (1)
Capital Medical University (1) · ENA Respiratory Pty Ltd (1) · Fluart Innovative Vaccine Ltd, Hungary (1) · PharmaJet, Inc. (1)
China (1) · Hungary (1) · United Kingdom (1) · United States (1)
Bin Cao, Ph.D (1) · Daniel Perlman, MD, MBA (1) · Victoria Parker, MD (1)